The famed Danish drug maker Novo Nordisk A/S (NYSE:NVO) expressed disappointment on Wednesday following a recommendation by the Dutch Health Care Institute advising the Netherlands government against including the company’s popular weight-loss drug, Wegovy, in the basic insurance coverage. The institute’s recommendation, delivered on Tuesday, cited insufficient clarity on whether Wegovy’s health benefits justify its costs. Related: Bernie Sanders Targets High Prices of Ozempic and Wegovy In US. Although Wegovy has proven effective for weight loss, the institute stressed the need for further research to determine the drug’s comprehensive health ...